ID   S22A1_HUMAN             Reviewed;         554 AA.
AC   O15245; A6NFF3; A8K1H2; C9JSU6; O15395; Q9NQD4;
DT   20-MAY-2008, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 2.
DT   10-MAY-2017, entry version 147.
DE   RecName: Full=Solute carrier family 22 member 1;
DE   AltName: Full=Organic cation transporter 1;
DE            Short=hOCT1;
GN   Name=SLC22A1; Synonyms=OCT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND VARIANT PHE-160.
RC   TISSUE=Liver;
RX   PubMed=9260930; DOI=10.1089/dna.1997.16.871;
RA   Gorboulev V., Ulzheimer J.C., Akhoundova A., Ulzheimer-Teuber I.,
RA   Karbach U., Quester S., Baumann C., Lang F., Busch A.E., Koepsell H.;
RT   "Cloning and characterization of two human polyspecific organic cation
RT   transporters.";
RL   DNA Cell Biol. 16:871-881(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND TISSUE SPECIFICITY.
RX   PubMed=9187257;
RA   Zhang L., Dresser M.J., Gray A.T., Yost S.C., Terashita S.,
RA   Giacomini K.M.;
RT   "Cloning and functional expression of a human liver organic cation
RT   transporter.";
RL   Mol. Pharmacol. 51:913-921(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), FUNCTION, TISSUE
RP   SPECIFICITY, AND ALTERNATIVE SPLICING (ISOFORMS 1; 2; 3 AND 4).
RX   PubMed=11388889; DOI=10.1046/j.1469-1809.2000.6430267.x;
RA   Hayer M., Boenisch H., Bruess M.;
RT   "Molecular cloning, functional characterization and genomic
RT   organization of four alternatively spliced isoforms of the human
RT   organic cation transporter 1 (hOCT1/SLC22A1).";
RL   Ann. Hum. Genet. 63:473-482(1999).
RN   [4]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Hayer M., Bonisch H., Bruss M.;
RL   Ann. Hum. Genet. 64:267-267(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   PHE-160; VAL-408; MET-420 DEL AND ARG-465.
RC   TISSUE=Caudate nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PHE-160.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9655880;
RA   Zhang L., Schaner M.E., Giacomini K.M.;
RT   "Functional characterization of an organic cation transporter (hOCT1)
RT   in a transiently transfected human cell line (HeLa).";
RL   J. Pharmacol. Exp. Ther. 286:354-361(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=11408531;
RA   van Montfoort J.E., Mueller M., Groothuis G.M.M., Meijer D.K.F.,
RA   Koepsell H., Meier P.J.;
RT   "Comparison of 'type I' and 'type II' organic cation transport by
RT   organic cation transporters and organic anion-transporting
RT   polypeptides.";
RL   J. Pharmacol. Exp. Ther. 298:110-115(2001).
RN   [10]
RP   FUNCTION.
RX   PubMed=15389554; DOI=10.1002/jcp.20081;
RA   Ciarimboli G., Struwe K., Arndt P., Gorboulev V., Koepsell H.,
RA   Schlatter E., Hirsch J.R.;
RT   "Regulation of the human organic cation transporter hOCT1.";
RL   J. Cell. Physiol. 201:420-428(2004).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16263091; DOI=10.1016/j.bcp.2005.09.011;
RA   Mueller J., Lips K.S., Metzner L., Neubert R.H.H., Koepsell H.,
RA   Brandsch M.;
RT   "Drug specificity and intestinal membrane localization of human
RT   organic cation transporters (OCT).";
RL   Biochem. Pharmacol. 70:1851-1860(2005).
RN   [12]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16272756; DOI=10.2133/dmpk.20.379;
RA   Kimura N., Masuda S., Tanihara Y., Ueo H., Okuda M., Katsura T.,
RA   Inui K.;
RT   "Metformin is a superior substrate for renal organic cation
RT   transporter OCT2 rather than hepatic OCT1.";
RL   Drug Metab. Pharmacokinet. 20:379-386(2005).
RN   [13]
RP   INDUCTION.
RX   PubMed=16436500; DOI=10.1124/jpet.105.099929;
RA   Saborowski M., Kullak-Ublick G.A., Eloranta J.J.;
RT   "The human organic cation transporter-1 gene is transactivated by
RT   hepatocyte nuclear factor-4alpha.";
RL   J. Pharmacol. Exp. Ther. 317:778-785(2006).
RN   [14]
RP   FUNCTION.
RX   PubMed=16581093; DOI=10.1016/j.neuropharm.2006.01.005;
RA   Amphoux A., Vialou V., Drescher E., Bruess M., Mannoury La Cour C.,
RA   Rochat C., Millan M.J., Giros B., Boenisch H., Gautron S.;
RT   "Differential pharmacological in vitro properties of organic cation
RT   transporters and regional distribution in rat brain.";
RL   Neuropharmacology 50:941-952(2006).
RN   [15]
RP   INDUCTION.
RX   PubMed=17635184; DOI=10.1111/j.1472-8206.2007.00517.x;
RA   Dias V., Ribeiro V.;
RT   "The expression of the solute carriers NTCP and OCT-1 is regulated by
RT   cholesterol in HepG2 cells.";
RL   Fundam. Clin. Pharmacol. 21:445-450(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-541, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   VARIANTS CYS-61; ARG-88; PHE-160; SER-401 AND MET-420 DEL, AND
RP   CHARACTERIZATION OF VARIANTS CYS-61; ARG-88; PHE-160; SER-401 AND
RP   MET-420 DEL.
RX   PubMed=12439218; DOI=10.1097/00008571-200211000-00002;
RA   Kerb R., Brinkmann U., Chatskaia N., Gorbunov D., Gorboulev V.,
RA   Mornhinweg E., Keil A., Eichelbaum M., Koepsell H.;
RT   "Identification of genetic variations of the human organic cation
RT   transporter hOCT1 and their functional consequences.";
RL   Pharmacogenetics 12:591-595(2002).
RN   [18]
RP   VARIANTS PHE-14; CYS-61; PHE-85; PHE-160; LEU-189; VAL-220; LEU-341;
RP   HIS-342; SER-401; VAL-408; MET-420 DEL; ILE-440; ILE-461; ARG-465 AND
RP   MET-488, CHARACTERIZATION OF VARIANTS PHE-14; CYS-61; PHE-85; PHE-160;
RP   LEU-189; VAL-220; LEU-341; HIS-342; SER-401; VAL-408; MET-420 DEL;
RP   ILE-440; ILE-461; ARG-465 AND MET-488, AND MUTAGENESIS OF GLY-465.
RX   PubMed=12719534; DOI=10.1073/pnas.0730858100;
RA   Shu Y., Leabman M.K., Feng B., Mangravite L.M., Huang C.C., Stryke D.,
RA   Kawamoto M., Johns S.J., DeYoung J., Carlson E., Ferrin T.E.,
RA   Herskowitz I., Giacomini K.M.;
RT   "Evolutionary conservation predicts function of variants of the human
RT   organic cation transporter, OCT1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5902-5907(2003).
RN   [19]
RP   VARIANTS PHE-160; LEU-283; GLY-287 AND LEU-341.
RX   PubMed=14697261; DOI=10.1016/j.bbrc.2003.11.175;
RA   Sakata T., Anzai N., Shin H.J., Noshiro R., Hirata T., Yokoyama H.,
RA   Kanai Y., Endou H.;
RT   "Novel single nucleotide polymorphisms of organic cation transporter 1
RT   (SLC22A1) affecting transport functions.";
RL   Biochem. Biophys. Res. Commun. 313:789-793(2004).
RN   [20]
RP   VARIANTS LEU-41; PHE-160; LEU-341 AND VAL-408.
RX   PubMed=15499200; DOI=10.2133/dmpk.19.308;
RA   Itoda M., Saito Y., Maekawa K., Hichiya H., Komamura K., Kamakura S.,
RA   Kitakaze M., Tomoike H., Ueno K., Ozawa S., Sawada J.;
RT   "Seven novel single nucleotide polymorphisms in the human SLC22A1 gene
RT   encoding organic cation transporter 1 (OCT1).";
RL   Drug Metab. Pharmacokinet. 19:308-312(2004).
CC   -!- FUNCTION: Translocates a broad array of organic cations with
CC       various structures and molecular weights including the model
CC       compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium
CC       (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-
CC       N-methylpyridinium (ASP), the endogenous compounds choline,
CC       guanidine, histamine, epinephrine, adrenaline, noradrenaline and
CC       dopamine, and the drugs quinine, and metformin. The transport of
CC       organic cations is inhibited by a broad array of compounds like
CC       tetramethylammonium (TMA), cocaine, lidocaine, NMDA receptor
CC       antagonists, atropine, prazosin, cimetidine, TEA and NMN,
CC       guanidine, cimetidine, choline, procainamide, quinine,
CC       tetrabutylammonium, and tetrapentylammonium. Translocates organic
CC       cations in an electrogenic and pH-independent manner. Translocates
CC       organic cations across the plasma membrane in both directions.
CC       Transports the polyamines spermine and spermidine. Transports
CC       pramipexole across the basolateral membrane of the proximal
CC       tubular epithelial cells. The choline transport is activated by
CC       MMTS. Regulated by various intracellular signaling pathways
CC       including inhibition by protein kinase A activation, and
CC       endogenously activation by the calmodulin complex, the calmodulin-
CC       dependent kinase II and LCK tyrosine kinase.
CC       {ECO:0000269|PubMed:11388889, ECO:0000269|PubMed:11408531,
CC       ECO:0000269|PubMed:15389554, ECO:0000269|PubMed:16272756,
CC       ECO:0000269|PubMed:16581093, ECO:0000269|PubMed:9187257,
CC       ECO:0000269|PubMed:9260930, ECO:0000269|PubMed:9655880}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.47 mM for metformin {ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:9187257, ECO:0000269|PubMed:9655880};
CC         KM=229 uM for TEA {ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:9187257, ECO:0000269|PubMed:9655880};
CC         KM=14.6 uM for MPP {ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:9187257, ECO:0000269|PubMed:9655880};
CC         Vmax=396 pmol/min/mg enzyme for metformin uptake
CC         {ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:9187257,
CC         ECO:0000269|PubMed:9655880};
CC         Vmax=2.89 nmol/min/mg enzyme for TEA uptake
CC         {ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:9187257,
CC         ECO:0000269|PubMed:9655880};
CC   -!- INTERACTION:
CC       Q96G23:CERS2; NbExp=3; IntAct=EBI-1172714, EBI-1057080;
CC   -!- SUBCELLULAR LOCATION: Basolateral cell membrane
CC       {ECO:0000269|PubMed:16263091}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:16263091}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=hOCT1G/L554;
CC         IsoId=O15245-1; Sequence=Displayed;
CC       Name=2; Synonyms=hOCT1G/L506;
CC         IsoId=O15245-2; Sequence=VSP_033589, VSP_033590;
CC       Name=3; Synonyms=hOCT1G483;
CC         IsoId=O15245-3; Sequence=VSP_033588;
CC       Name=4; Synonyms=hOCT1G353;
CC         IsoId=O15245-4; Sequence=VSP_033587;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC   -!- TISSUE SPECIFICITY: Widely expressed with high level in liver.
CC       Isoform 1 and isoform 2 are expressed in liver. Isoform 1, isoform
CC       2, isoform 3 and isoform 4 are expressed in glial cell lines.
CC       {ECO:0000269|PubMed:11388889, ECO:0000269|PubMed:9187257,
CC       ECO:0000269|PubMed:9260930}.
CC   -!- INDUCTION: In the liver activated by HNF4A and suppressed by bile
CC       acids via NR0B2. Increased by cholesterol treatment in hepatocyte
CC       cells. {ECO:0000269|PubMed:16436500, ECO:0000269|PubMed:17635184}.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1)
CC       superfamily. Organic cation transporter (TC 2.A.1.19) family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X98332; CAA66977.1; -; mRNA.
DR   EMBL; U77086; AAB67703.1; -; mRNA.
DR   EMBL; AJ243995; CAB95971.1; -; Genomic_DNA.
DR   EMBL; AJ243996; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AJ243998; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AJ243999; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AJ244000; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AJ245460; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AJ276051; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AJ276052; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AJ276053; CAB95971.1; JOINED; Genomic_DNA.
DR   EMBL; AK289887; BAF82576.1; -; mRNA.
DR   EMBL; AL353625; CAH72016.1; -; Genomic_DNA.
DR   EMBL; BC126364; AAI26365.1; -; mRNA.
DR   CCDS; CCDS5274.1; -. [O15245-1]
DR   CCDS; CCDS5275.1; -. [O15245-2]
DR   RefSeq; NP_003048.1; NM_003057.2. [O15245-1]
DR   RefSeq; NP_694857.1; NM_153187.1. [O15245-2]
DR   RefSeq; XP_006715615.1; XM_006715552.1. [O15245-3]
DR   UniGene; Hs.117367; -.
DR   ProteinModelPortal; O15245; -.
DR   BioGrid; 112467; 1.
DR   IntAct; O15245; 1.
DR   STRING; 9606.ENSP00000355930; -.
DR   BindingDB; O15245; -.
DR   ChEMBL; CHEMBL5685; -.
DR   DrugBank; DB01193; Acebutolol.
DR   DrugBank; DB01614; Acepromazine.
DR   DrugBank; DB03128; Acetylcholine.
DR   DrugBank; DB00787; Aciclovir.
DR   DrugBank; DB08838; Agmatine.
DR   DrugBank; DB00915; Amantadine.
DR   DrugBank; DB00594; Amiloride.
DR   DrugBank; DB00345; Aminohippuric acid.
DR   DrugBank; DB04830; Buformin.
DR   DrugBank; DB00520; Caspofungin.
DR   DrugBank; DB01114; Chlorphenamine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB00122; Choline.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB00242; Cladribine.
DR   DrugBank; DB00575; Clonidine.
DR   DrugBank; DB00318; Codeine.
DR   DrugBank; DB00987; Cytarabine.
DR   DrugBank; DB04485; Deoxythymidine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB01075; Diphenhydramine.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB04574; Estrone sulfate.
DR   DrugBank; DB01004; Ganciclovir.
DR   DrugBank; DB00406; Gentian Violet.
DR   DrugBank; DB00536; Guanidine.
DR   DrugBank; DB00667; Histamine Phosphate.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB00224; Indinavir.
DR   DrugBank; DB00709; Lamivudine.
DR   DrugBank; DB00654; Latanoprost.
DR   DrugBank; DB00331; Metformin.
DR   DrugBank; DB00683; Midazolam.
DR   DrugBank; DB00220; Nelfinavir.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00526; Oxaliplatin.
DR   DrugBank; DB01337; Pancuronium.
DR   DrugBank; DB00914; Phenformin.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB01621; Pipotiazine.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB00457; Prazosin.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB01035; Procainamide.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00468; Quinine.
DR   DrugBank; DB00863; Ranitidine.
DR   DrugBank; DB00206; Reserpine.
DR   DrugBank; DB00728; Rocuronium.
DR   DrugBank; DB01232; Saquinavir.
DR   DrugBank; DB03566; Spermidine.
DR   DrugBank; DB00127; Spermine.
DR   DrugBank; DB04348; Taurocholic Acid.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB08837; Tetraethylammonium.
DR   DrugBank; DB00152; Thiamine.
DR   DrugBank; DB01622; Thioproperazine.
DR   DrugBank; DB01623; Thiothixene.
DR   DrugBank; DB01199; Tubocurarine.
DR   DrugBank; DB01339; Vecuronium.
DR   DrugBank; DB00661; Verapamil.
DR   GuidetoPHARMACOLOGY; 1019; -.
DR   TCDB; 2.A.1.19.29; the major facilitator superfamily (mfs).
DR   iPTMnet; O15245; -.
DR   PhosphoSitePlus; O15245; -.
DR   BioMuta; SLC22A1; -.
DR   PaxDb; O15245; -.
DR   PeptideAtlas; O15245; -.
DR   PRIDE; O15245; -.
DR   DNASU; 6580; -.
DR   Ensembl; ENST00000324965; ENSP00000318103; ENSG00000175003. [O15245-2]
DR   Ensembl; ENST00000366963; ENSP00000355930; ENSG00000175003. [O15245-1]
DR   Ensembl; ENST00000457470; ENSP00000409557; ENSG00000175003. [O15245-3]
DR   Ensembl; ENST00000460902; ENSP00000439274; ENSG00000175003. [O15245-4]
DR   GeneID; 6580; -.
DR   KEGG; hsa:6580; -.
DR   UCSC; uc003qtc.4; human. [O15245-1]
DR   CTD; 6580; -.
DR   DisGeNET; 6580; -.
DR   GeneCards; SLC22A1; -.
DR   HGNC; HGNC:10963; SLC22A1.
DR   HPA; HPA029846; -.
DR   MIM; 602607; gene.
DR   neXtProt; NX_O15245; -.
DR   OpenTargets; ENSG00000175003; -.
DR   PharmGKB; PA329; -.
DR   eggNOG; KOG0255; Eukaryota.
DR   eggNOG; COG0477; LUCA.
DR   GeneTree; ENSGT00760000118852; -.
DR   HOGENOM; HOG000234568; -.
DR   HOVERGEN; HBG061545; -.
DR   InParanoid; O15245; -.
DR   KO; K08198; -.
DR   OMA; DLFQSCL; -.
DR   OrthoDB; EOG091G05AC; -.
DR   PhylomeDB; O15245; -.
DR   TreeFam; TF315847; -.
DR   Reactome; R-HSA-112311; Neurotransmitter Clearance In The Synaptic Cleft.
DR   Reactome; R-HSA-181430; Norepinephrine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-2161517; Abacavir transmembrane transport.
DR   Reactome; R-HSA-442660; Na+/Cl- dependent neurotransmitter transporters.
DR   Reactome; R-HSA-549127; Organic cation transport.
DR   GeneWiki; SLC22A1; -.
DR   GenomeRNAi; 6580; -.
DR   PRO; PR:O15245; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000175003; -.
DR   CleanEx; HS_SLC22A1; -.
DR   ExpressionAtlas; O15245; baseline and differential.
DR   Genevisible; O15245; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005277; F:acetylcholine transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0005329; F:dopamine transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0005333; F:norepinephrine transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0008514; F:organic anion transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015101; F:organic cation transmembrane transporter activity; EXP:Reactome.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0015651; F:quaternary ammonium group transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0008513; F:secondary active organic cation transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015872; P:dopamine transport; IBA:GO_Central.
DR   GO; GO:0006855; P:drug transmembrane transport; TAS:Reactome.
DR   GO; GO:0048241; P:epinephrine transport; IEA:Ensembl.
DR   GO; GO:0010248; P:establishment or maintenance of transmembrane electrochemical gradient; IEA:Ensembl.
DR   GO; GO:0006836; P:neurotransmitter transport; IBA:GO_Central.
DR   GO; GO:0015874; P:norepinephrine transport; IBA:GO_Central.
DR   GO; GO:0015695; P:organic cation transport; TAS:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:Ensembl.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR004749; Orgcat_transp/SVOP.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   Pfam; PF00083; Sugar_tr; 2.
DR   SUPFAM; SSF103473; SSF103473; 1.
DR   TIGRFAMs; TIGR00898; 2A0119; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   PROSITE; PS00216; SUGAR_TRANSPORT_1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome; Glycoprotein;
KW   Ion transport; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    554       Solute carrier family 22 member 1.
FT                                /FTId=PRO_0000333875.
FT   TOPO_DOM      1     21       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     22     42       Helical. {ECO:0000255}.
FT   TOPO_DOM     43    149       Extracellular. {ECO:0000255}.
FT   TRANSMEM    150    170       Helical. {ECO:0000255}.
FT   TOPO_DOM    171    176       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    177    197       Helical. {ECO:0000255}.
FT   TOPO_DOM    198    206       Extracellular. {ECO:0000255}.
FT   TRANSMEM    207    229       Helical. {ECO:0000255}.
FT   TOPO_DOM    230    235       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    236    256       Helical. {ECO:0000255}.
FT   TOPO_DOM    257    262       Extracellular. {ECO:0000255}.
FT   TRANSMEM    263    283       Helical. {ECO:0000255}.
FT   TOPO_DOM    284    347       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    348    368       Helical. {ECO:0000255}.
FT   TOPO_DOM    369    376       Extracellular. {ECO:0000255}.
FT   TRANSMEM    377    397       Helical. {ECO:0000255}.
FT   TOPO_DOM    398    402       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    403    423       Helical. {ECO:0000255}.
FT   TOPO_DOM    424    431       Extracellular. {ECO:0000255}.
FT   TRANSMEM    432    452       Helical. {ECO:0000255}.
FT   TOPO_DOM    453    464       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    465    485       Helical. {ECO:0000255}.
FT   TOPO_DOM    486    492       Extracellular. {ECO:0000255}.
FT   TRANSMEM    493    513       Helical. {ECO:0000255}.
FT   TOPO_DOM    514    554       Cytoplasmic. {ECO:0000255}.
FT   SITE        450    450       Involved in affinity and selectivity of
FT                                cations as well as in translocation.
FT                                {ECO:0000250}.
FT   MOD_RES     333    333       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08966}.
FT   MOD_RES     541    541       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     71     71       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     354    554       Missing (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_033587.
FT   VAR_SEQ     462    532       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_033588.
FT   VAR_SEQ     462    506       RNLGVMVCSSLCDIGGIITPFIVFRLREVWQALPLILFAVL
FT                                GLLA -> SGVGPACRGSDATSSRDQGGRFARDHEGRREPW
FT                                EKSKAQRKHDLP (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_033589.
FT   VAR_SEQ     507    554       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_033590.
FT   VARIANT      14     14       S -> F (exclusively found in the African
FT                                American population; increase of the MPP
FT                                uptake when associated with V-408;
FT                                dbSNP:rs34447885).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043319.
FT   VARIANT      41     41       F -> L (in dbSNP:rs2297373).
FT                                {ECO:0000269|PubMed:15499200}.
FT                                /FTId=VAR_043320.
FT   VARIANT      61     61       R -> C (affects transporter activity;
FT                                reduction of the MPP uptake when
FT                                associated with V-408; dbSNP:rs12208357).
FT                                {ECO:0000269|PubMed:12439218,
FT                                ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043321.
FT   VARIANT      85     85       L -> F (no changes in the MPP uptake when
FT                                associated with V-408; dbSNP:rs35546288).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043322.
FT   VARIANT      88     88       C -> R (in dbSNP:rs55918055).
FT                                {ECO:0000269|PubMed:12439218}.
FT                                /FTId=VAR_043323.
FT   VARIANT     160    160       L -> F (no changes in both TEA and MPP
FT                                uptake; abolishes MPP uptake when
FT                                associated with S-401; largely localized
FT                                to the plasma membrane; dbSNP:rs683369).
FT                                {ECO:0000269|PubMed:12439218,
FT                                ECO:0000269|PubMed:12719534,
FT                                ECO:0000269|PubMed:14697261,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15499200,
FT                                ECO:0000269|PubMed:9260930}.
FT                                /FTId=VAR_043324.
FT   VARIANT     189    189       S -> L (no changes in the MPP uptake;
FT                                dbSNP:rs34104736).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043325.
FT   VARIANT     220    220       G -> V (affects MPP uptake; reduction of
FT                                the MPP uptake when associated with V-
FT                                408; dbSNP:rs36103319).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043326.
FT   VARIANT     283    283       P -> L (in dbSNP:rs4646277).
FT                                {ECO:0000269|PubMed:14697261}.
FT                                /FTId=VAR_043327.
FT   VARIANT     287    287       R -> G (in dbSNP:rs4646278).
FT                                {ECO:0000269|PubMed:14697261}.
FT                                /FTId=VAR_043328.
FT   VARIANT     341    341       P -> L (affects transporter activity;
FT                                reduction of the TEA uptake; reduction of
FT                                the MPP uptake when associated with V-
FT                                408; largely localized to the plasma
FT                                membrane; dbSNP:rs2282143).
FT                                {ECO:0000269|PubMed:12719534,
FT                                ECO:0000269|PubMed:14697261,
FT                                ECO:0000269|PubMed:15499200}.
FT                                /FTId=VAR_043329.
FT   VARIANT     342    342       R -> H (no changes in the MPP uptake when
FT                                associated with V-408; dbSNP:rs34205214).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043330.
FT   VARIANT     401    401       G -> S (affects transporter activity;
FT                                reduction of the serotonin uptake; no MPP
FT                                uptake when associated with L-160;
FT                                dbSNP:rs34130495).
FT                                {ECO:0000269|PubMed:12439218,
FT                                ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043331.
FT   VARIANT     408    408       M -> V (does not affect transporter
FT                                activity; no changes in the MPP uptake
FT                                when associated with F-14; no changes in
FT                                the MPP uptake when associated with F-85;
FT                                no changes in the MPP uptake when
FT                                associated with L-189; no changes in the
FT                                MPP uptake when associated with His-342;
FT                                no changes in the MPP uptake when
FT                                associated with M-420 del; no changes in
FT                                the MPP uptake when associated with I-
FT                                440; no changes in the MPP uptake when
FT                                associated with I-461; no changes in the
FT                                MPP uptake when associated with M-488;
FT                                reduction of the MPP uptake when
FT                                associated with C-61; no MPP uptake when
FT                                associated with V-220; reduction of the
FT                                MPP uptake when associated with L-341; no
FT                                MPP uptake when associated with S-401; no
FT                                MPP uptake when associated with R-465;
FT                                dbSNP:rs628031).
FT                                {ECO:0000269|PubMed:12719534,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15499200}.
FT                                /FTId=VAR_043332.
FT   VARIANT     420    420       Missing (no changes in the MPP uptake
FT                                when associated with V-408).
FT                                {ECO:0000269|PubMed:12439218,
FT                                ECO:0000269|PubMed:12719534,
FT                                ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_043333.
FT   VARIANT     440    440       M -> I (in dbSNP:rs35956182).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043334.
FT   VARIANT     461    461       V -> I (no changes in the MPP uptake when
FT                                associated with V-408; dbSNP:rs34295611).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043335.
FT   VARIANT     465    465       G -> R (reduction of the localization to
FT                                the basolateral membrane; no MPP uptake
FT                                when associated with V-408;
FT                                dbSNP:rs34059508).
FT                                {ECO:0000269|PubMed:12719534,
FT                                ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_043336.
FT   VARIANT     488    488       R -> M (no changes in the MPP uptake when
FT                                associated with V-408; dbSNP:rs35270274).
FT                                {ECO:0000269|PubMed:12719534}.
FT                                /FTId=VAR_043337.
FT   MUTAGEN     465    465       G->A: No changes in the MPP uptake.
FT                                {ECO:0000269|PubMed:12719534}.
SQ   SEQUENCE   554 AA;  61154 MW;  55206B897DE32202 CRC64;
     MPTVDDILEQ VGESGWFQKQ AFLILCLLSA AFAPICVGIV FLGFTPDHHC QSPGVAELSQ
     RCGWSPAEEL NYTVPGLGPA GEAFLGQCRR YEVDWNQSAL SCVDPLASLA TNRSHLPLGP
     CQDGWVYDTP GSSIVTEFNL VCADSWKLDL FQSCLNAGFL FGSLGVGYFA DRFGRKLCLL
     GTVLVNAVSG VLMAFSPNYM SMLLFRLLQG LVSKGNWMAG YTLITEFVGS GSRRTVAIMY
     QMAFTVGLVA LTGLAYALPH WRWLQLAVSL PTFLFLLYYW CVPESPRWLL SQKRNTEAIK
     IMDHIAQKNG KLPPADLKML SLEEDVTEKL SPSFADLFRT PRLRKRTFIL MYLWFTDSVL
     YQGLILHMGA TSGNLYLDFL YSALVEIPGA FIALITIDRV GRIYPMAMSN LLAGAACLVM
     IFISPDLHWL NIIIMCVGRM GITIAIQMIC LVNAELYPTF VRNLGVMVCS SLCDIGGIIT
     PFIVFRLREV WQALPLILFA VLGLLAAGVT LLLPETKGVA LPETMKDAEN LGRKAKPKEN
     TIYLKVQTSE PSGT
//
